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Summary.-A study of granulocyte function in myeloblastic leukaemia is reported.
Function was assessed by the ability of peripheral blood granulocytes to ingest
and kill Candida albicans in vitro. Depressed cidal activity was observed in 11
patients withsmouldering leukaemia and in19 patients withacute myeloidleukaemia.
Cidal activity was lowest in the untreated acute disease; this improved during cyto-
reduction therapy and was maintained when remission occurred. Leukaemic
plasma depressed the function of control granulocytes; the possible role of a
plasma " factor " is discussed.
THE NATURAL history of acute leu- sixth MRC trial, but had received no therapy
kaemia is characterized by the develop- for 7 days before the assay.
ment of frequent and severe infections, The term " smouldering leukaemia " (SL)
and infection is a major cause of death (Drayfus, Sultan and Manonni, 1970) was
(Hersch et al., 1965). Various theories applied to those patients with abnormalities
have been proposed to explain the in- of the peripheral blood and/or bone marrow
creased incidence of infection. Hirschen in which the percentage of blast cells in the ceres incidencastheofinfection.epo Hirse marrow, whilst similar in morphology, was berg (1939) was the first to report impaired substantially less than in AML and did not
phagocytosis in acute leukaemia, an account for more than 30% of the total
observation that has since been confirmed marrow cells. Most of these patients were
by many workers. anaemic, thrombocytopenic and many granu-
The purpose of this study was to locytopenic. Two patients were receiving
examine granulocyte function in myelo- daily prednisolone and blood transfusions
blastic leukaemia at various stages of the when indicated. The remainder were not
disease. The results are presented and the receiving chemotherapy or immunotherapy.
findings discussed. Control samples were obtained from
healthy hospital personnel.
The effect ofdrug therapy on granulocyte PATIENTS AND METHODS function was assessed by incubating sepa-
Patients andcontrols.-All patients studied rately control cells with hydrocortisone
had an unequivocal diagnosis of myeloblastic (30 ,tg/ml), daunorubicin (3 ,ug/ml) and cyto-
leukaemia on the basis of clinical, peripheral sine arabinoside (0.6 ,ug/ml).
blood and bone marrow examination. The Student's " t " test was employed to
term acute myeloid leukaemia (AML) em- assess differences between the mean scores.
braces all the morphological forms. Patients Assay.-The technique for assay was that
were investigated at presentation, during described by Lehrer and Cline (1969) as
induction therapy and when in remission. modified by Goldman and Th'ng (1973).
Those receiving drug therapy had no chemo- Candida albicans was maintained on
therapy for 5 days before the assay. Patients glucose-peptone agar at room temperature.
in remission were concurrently receiving Only cultures containing more than 95% of
immunotherapy with weekly injections of viable cells were used for the assay. Equal
BCG and irradiated blast cells as part of the volumes (0.25 ml) of leucocyte suspension,
* Present address: Consultant in Clinical Pharmacology, Christie Hospital and Holt Radium Institute,
Manchester.GRANULOCYTE FUNCTION IN MYELOBLASTIC LEUKAEMIA 575
autologous plasma and Hanks' balanced salt The values obtained in granulocytic
solution (HBSS) were placed in sterile con- leukaemia are shown in Table I. Patients
tainers and a suspension of Candida albicans with both smouldering leukaemia and
added to provide a neutrophil : Candida ratio AML had a significantly reduced index
of 1 : 1. Each estimation was performed compared with control subjects. The
with control leucocytes and a blank tube cmaed w it control subjets th
containing plasma HBSS and Candida albi- index was most impaired in patients with
cans, but no leucocytes. untreated AML (3.1 i 0t6%); but im-
Tubes were incubated at 37°C for 1 h. proved during induction therapy (6.6 ±
After 30 min a small sample was withdrawn 1-5%), and later when in remission
to confirm that all the added organisms had (8.7 + 1.1%). The difference in Candi-
been ingested. At 1 h Na deoxycholate dacidal index between the 4 groups was
(pH 8.7) was added to lyse the leucocytes and statistically significant (Table II).
5 min later methylene blue (0.25%) was The effects of leukaemic plasma on
added and the suspension centrifuged. From normal granulocyte function are shown
a wet preparation of each cell sediment 500 in Table III. In allgroups, the incubation
Candida cells were counted (dead cells stain of normal granulocytes with leukaemic
a uniform intense blue). The Candidacidal plasma significantly depressed the index.
index (%) was calculated as follows: pa wit unt reated the the In patients with untreated AML, the
Total number dead cells- addition of normal plasma to leukaemic
number dead in control tube. cells significantly increased the index.
5 Cytosine arabinoside and hydrocorti-
sone did not depress the Candidacidal
RESULTS index in control subjects.- The index fell
Sixteen control subjects and 30 patients to 8% when cells were incubated with
with leukaemia were studied. Nineteen daunorubicin.
patients had AML (7 untreated, 6 were
receiving drug therapy and 6 immuno- DISCUSSION
therapy) and 11 patients smouldering Various in vitro techniques are avail-
leukaemia. able to assess granulocyte function. The
The Candidacidal index in control method used in this study was chosen
subjects was 12-4 ± 2.4% (range 10-18) because of the reproducibility of the test
and was highly reproducible. and because Candidiasis is the most
TABLE I.-Candidacidal Index (%) in 30 Patients with Granulocytic Leukaemia
Candidacidal index
Disease No. Mean ± s.d. Range
SL 11 7.16+0.75* 6 4-8 0
AML (new) 7 3 1±1 6t 0-4 8
AML (induction) 6 6.6±1.46* 4-8
AML (immunotherapy) 6 8.7±1.1* 8-10 6
Values were compared with control subjects; an asterisk indicates a significant difference.
*P < 0-05, tP < 0 01 two-tailed. (For normal values see text.)
TABLE II.-Difference in Candidacidal Index (%) in Smouldering and Acute
Myeloid Leuqkaemia
Group Difference Group Difference
SL vs AML (new) 4-0t AML (new) Vs AML (induction) 3-5*
SL v8 AML (induction) 0-6 AML (new) vs AML (immunotherapy) 5-6t
SL v8 AML (immunotherapy) 1.5* AML (induction) vs AML (immunotherapy) 2.1*
* P < 0 01 two-tailed, t P < 0 001 two-tailed.
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TABLE III.-Candidacidal Index in Granulocytic Leukaemia; Effect of Leukaemic
Plasma on Control Granulocytes and Control plasma on Leukaemic Granulocytes
Candidacidal index %




Autologous Control Autologous Leukaemic
Group No. plasma plasma Difference plasma plasma Difference
SL 11 7.2±0i75 7 6±0 i78 0 4 10 5±0i9 9 24i0 8 1.3*
AML (new) 7 3d1±1.6 5 2±3i6 2.1* 111i±2-3 8 1±008 3.0*
AML (induction) 6 6-6±1i4 8-5±2i7 1.9 11 8±12 8 8±1 6 3.0*
AML (immunotherapy) 6 8 7±1i1 9 4+1i0 0 7 12 0±16 10 3±2i1 1 7*
*P = 0*05 two-tailed.
frequent fungal complication in leukaemia range, implying that the cell is still
(Bodey, 1966). Because of the ratio of functionally abnormal and may support
cells to organisms employed, the test is of the view that granulocytes in AML in
value in assessing cidal but not phagocytic remission are derived from persistently
properties of granulocytes. abnormal stem cells. Hudson and Wilson
Granulocyte function in leukaemia has (1960) also observed that leucocytes from
been studied extensively. The observa- patients in remission had decreased bac-
tion that granulocytes obtained from tericidal activity. This functional abnor-
patients with AML have an impaired mality may be due to persistent enzyme
ability to kill Candida albicans confirms defects within the cell; such defects have
the results of previous workers (Lehrer been observed by other workers (Skeel,
and Cline, 1971; Goldman and Th'ng, Yankee and Henderson, 1971; Strauss
1973). There is, however, little work on et al., 1970).
granulocyte function in smouldeting leu- Other factors not specific to leukaemia
kaemia, though these patients also show a may depress the Candidacidal index, e.g.
high incidence of infection. In these iron deficiency (Chandra, 1973) and ab-
patients, specific therapy is not normally normal immunoglobulin status (de Cree
indicated during the " smouldering " et al., 1974). There was no evidence of
phase of the disease and transfusion iron deficiency in the patients studied and
requirements are often minimal. Bac- in most instances immunoglobulin levels
terial infections, however, are common were within the normal range. Comple-
and impaired bactericidal activity has ment levels were not assessed but Fahey
been demonstrated in vitro (Lehrer et al., and Boggs (1960) found no consistent
1973). This study provides further evi- abnormality in complement levels in
dence of defective granulocyte function. acute leukaemia. The presence of anti-
The functional capacity ofthe granulocyte bodies against Candida albicans would not
in SL is greater than that observed in the produce a low index as the anti-Candida
acute phase of the disease. The Candida- antibody does not kill or lyse Candida
cidal index in the 2 patients in whom the organisms in vitro (Lehrer and Cline,
acute phase was imminent fell to that 1969). We found no evidence that blast
observed in untreated AML, suggesting cells or immature granulocytes had sig-
that there is a gradual impairment of nificant cidal activity, confirming the
function as the disease progresses. observations ofother workers (Silver et al.,
In AML granulocyte function im- 1957; Lichtman and Weed, 1972). While
proved significantly during induction daunorubicin was found to depress normal
therapy (Table II) and this was main- granulocyte function, because of the
tained when remission occurred (Table I). interval between administration and per-
The index did not return to the normal forming the assay (10 days) the drugGRANULOCYTE FUNCTION IN MYELOBLASTIC LEUKAEMIA 577
residue remaining in the body was negli-
gible and unlikely to invalidate the assay.
Thus, the observed defect in granulocyte
function must reflect an intrinsic abnor-
mality.
While previous studies have generally
been concerned with the granulocyte, little
attention has beeil paid to extrinsic
factors. The effects of leukaemic plasma
on normal granulocyte function was first
noted by Braude, Feltes and Brooks
(1954) and later by Goldman and Th'ng
(1973).
Plasma from patients with acute AML
depressed the cidal capacity of normal
granulocytes. The explanation of this
phenomenon must remain a matter for
conjecture for the present. There is some
evidence to suggest that it be due in part
to a factor released from the leukaemic
blast cell. The Candidacidal index in
patients with untreated AML improved
when granulocytes were incubated with
control plasma (Table III) but not when
remission occurred. Therewasno evidence
that granulocyte function in smouldering
leukaemia was related to the number of
blast cells in the blood. Mir and Bobinski
(1975) observed that a blast cell extract
impaired the sodium " pump " of normal
red blood corpuscles. These observations
suggest the presence of an enzyme in-
hibitor, probably a protein, which may
have protean effects on cell function.
Leukaemic plasma from patients with
AML in remission and with smouldering
leukaemia also depressed normal function.
Patients in remission had received several
blood transfusions and weekly injections
of BCG and allogeneic blast cells; the
resulting antibody production may have
impaired normal function. Patients with
smouldering leukaemia, however, were
receiving neither blood transfusions nor
specific drug therapy. The ability of
plasma to depress normal function in these
patients may be due to the development
of an abnormal protein which further
impairs granulocyte function when the
acute stage develops.
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